In comparison to wild-type tumors, in the ES-NSCLC cohort, PD-L1 expression levels were very low only in the presence of EGFR mutations, whereas, in advanced tumors, PD-L1 was greatly expressed in cases harboring BRAF p.(V600E), KRAS, and MET exon 14 skipping alterations and gene fusions. This evidence concerns the gene BRAF and non-small cell lung carcinoma.